MD ANDERSON CANCER CENTER and TESARO Inc. announced a collaboration to discover and develop small molecule product candidates against immuno-oncology targets, through the cancer center’s Institute for Applied Cancer Science. Under the agreement, TESARO will receive exclusive worldwide rights to develop and commercialize any small molecule product candidates that result from this collaboration. MD Anderson...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
